-
Signature
-
/s/ Christine Fox, by power of attorney
-
Stock symbol
-
MREO
-
Transactions as of
-
May 22, 2024
-
Transactions value $
-
-$383,131
-
Form type
-
4
-
Date filed
-
5/23/2024, 09:54 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
MREO |
American Depositary Shares representing Ordinary Shares |
Options Exercise |
$131K |
+93.3K |
+1220.04% |
$1.40 |
101K |
May 22, 2024 |
Direct |
F1, F2 |
transaction |
MREO |
American Depositary Shares representing Ordinary Shares |
Sale |
-$151K |
-50.4K |
-46.2% |
$2.99 |
58.6K |
May 22, 2024 |
Direct |
F1, F2, F3 |
transaction |
MREO |
American Depositary Shares representing Ordinary Shares |
Tax liability |
-$60.2K |
-43K |
-84.89% |
$1.40 |
7.65K |
May 22, 2024 |
Direct |
F1, F2 |
transaction |
MREO |
American Depositary Shares representing Ordinary Shares |
Options Exercise |
$75.8K |
+75K |
+980.39% |
$1.01 |
82.7K |
May 22, 2024 |
Direct |
F1, F2 |
transaction |
MREO |
American Depositary Shares representing Ordinary Shares |
Sale |
-$147K |
-50.1K |
-60.6% |
$2.94 |
32.6K |
May 22, 2024 |
Direct |
F1, F2, F3 |
transaction |
MREO |
American Depositary Shares representing Ordinary Shares |
Tax liability |
-$25.2K |
-24.9K |
-76.51% |
$1.01 |
7.65K |
May 22, 2024 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
MREO |
Share Options (Right to buy) |
Options Exercise |
-$131K |
-93.3K |
-100% |
$1.40 |
0 |
May 22, 2024 |
American Depositary Shares |
93.3K |
$1.40 |
Direct |
F1, F2, F4 |
transaction |
MREO |
Share Options (Right to buy) |
Options Exercise |
-$75.8K |
-75K |
-100% |
$1.01 |
0 |
May 22, 2024 |
American Depositary Shares |
75K |
$1.01 |
Direct |
F1, F2, F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Chief Patient Access and Commercial Planning